{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:09:43Z","timestamp":1720609783808},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1157\/13126270","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T18:15:16Z","timestamp":1227377716000},"page":"31-37","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S8","title":["Papel de tenofovir en la coinfecci\u00f3n por el virus de la inmunodeficiencia humana y el virus de la hepatitis C"],"prefix":"10.1016","volume":"26","author":[{"given":"Paula","family":"Tuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126270_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2893.2007.00903.x","article-title":"Liver cirrhosis in HIV-infected patients: prevalence, etiology and clinical outcome","volume":"15","author":"Castellares","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib2","unstructured":"L\u00e9dinghen V, Barreiro P, Foucher J, Labarga P, Cast\u00e9ra L, Vispo ME, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV- positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. En prensa 2008."},{"key":"10.1157\/13126270_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of HIV infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"10.1157\/13126270_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.20626","article-title":"HIV Coinfection shortens the survival of patients with hepatitis C virus-related decompensate cirrhosis","volume":"41","author":"Pineda","year":"2005","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib5","first-page":"131","article-title":"Management of HCV-related end-stage liver disease in HIV-coinfected patients","volume":"9","author":"Merchante","year":"2007","journal-title":"AIDS Rev"},{"key":"10.1157\/13126270_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00042560-200104150-00011","article-title":"Relation between HIV-1 and hepatitis C viral load in patients with hemophilia","volume":"26","author":"Daar","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/gut.2005.083758","article-title":"Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in HIV\/hepatitis C virus coinfected patients","volume":"55","author":"Harcourt","year":"2006","journal-title":"Gut"},{"key":"10.1157\/13126270_bib9","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1002\/eji.200535035","article-title":"Differences in HCVspecific T cell responses between chronic HCV infection and HIV\/HCV co-infection","volume":"35","author":"Dutoit","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1157\/13126270_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAD.0b013e3282f3553b","article-title":"Intrahepatic mRNA expression in hepatitis C virus (HCV) and HIV\/HCV co-infection: infiltrating cells, cytokines and influence of HAART","volume":"22","author":"Kuntzen","year":"2008","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib11","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV\/HCV co-infection","author":"Tuyama","year":"2008"},{"key":"10.1157\/13126270_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350801300111","article-title":"Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome","volume":"13","author":"Maida","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/499055","article-title":"Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?","volume":"42","author":"Verma","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1468-1293.2006.00384.x","article-title":"Risk factors for fibrosis progression in HIV\/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002","volume":"7","author":"Schiavini","year":"2006","journal-title":"HIV Med"},{"key":"10.1157\/13126270_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/hep.21757","article-title":"Clinical progression of hepatitis C virus-related chronic liver disease in HIV-infected patients undergoing highly active antiretroviral therapy","volume":"46","author":"Pineda","year":"2007","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Br\u00e4u","year":"2006","journal-title":"J Hepatology"},{"key":"10.1157\/13126270_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib18","series-title":"15th Conference on Retroviruses and Opportunistic Infections","author":"Blanco","year":"2008"},{"key":"10.1157\/13126270_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in HIV-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib20","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/00002030-200411050-00008","article-title":"Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV\/hepatitis C virus co-infected patients","volume":"18","author":"Marin\u00e9-Barjoan","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/135965350601100701","article-title":"Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C","volume":"11","author":"Mac\u00edas","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/524080","article-title":"Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection","volume":"46","author":"Berenguer","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib23","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/QAD.0b013e3282f10de9","article-title":"Rapid fibrosis progression among HIV\/hepatitis C virus-co-infected adults","volume":"21","author":"Sulkowski","year":"2007","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1157\/13126270_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib26","first-page":"371","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"14","author":"Labarga","year":"2007","journal-title":"J Viral Hepatitis"},{"key":"10.1157\/13126270_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with memevirapine or efvirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkauski","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/aid.2006.22.139","article-title":"Liver enzime elevation in Hepatitis C virus (HCV): HIV co-infected patients prior and after initiation of HAART: role of HCV genotypes","volume":"22","author":"Maida","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13126270_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00042560-200205010-00008","article-title":"Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy","volume":"30","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1089-3261(03)00023-0","article-title":"Antiretroviral-associated liver injury","volume":"7","author":"Ogedegbe","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1157\/13126270_bib32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","article-title":"Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway","volume":"12","author":"Brinkman","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/088922204322996491","article-title":"Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy","volume":"20","author":"Mendoza","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13126270_bib34","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with HIV infection: a report of 12 cases","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/527565","article-title":"Progression of fibrosis in HIV and hepatitis C Virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors","volume":"46","author":"Bani-Sadr","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126270_bib37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/gast.2002.30983","article-title":"Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein","volume":"122","author":"Okuda","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13126270_bib38","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1157\/13126270_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.qai.0000221683.44940.62","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs","volume":"42","author":"Maida","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/QAD.0b013e3280119e47","article-title":"Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients","volume":"21","author":"Mallet","year":"2007","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00126334-200404150-00014","article-title":"Hepatotoxicity associated with nevirapine use","volume":"35","author":"Baylor","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine","volume":"18","author":"Mac\u00edas","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1157\/13126270_bib44","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e3280110cae","article-title":"Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells\/microl","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Mart\u00ednez","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.3.1.9","article-title":"Tipranavir: a novel second-generation non-peptidic protease inhibitor","volume":"3","author":"Kandula","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1157\/13126270_bib48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1157\/13126270_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","article-title":"Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV\/HIV-coinfected patients","volume":"11","author":"Barreiro","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib50","unstructured":"Berenguer J, \u00c1lvarez-Pellicer J, L\u00f3pez-Aldeguer J, Von-Wichman M, Quereda C, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in HIV\/HCV-coinfected patients. 15th Conference on Retroviruses and Opportunistic Infections. Boston MA. 3-6 de febrero de 2008. Astract 60."},{"key":"10.1157\/13126270_bib51","first-page":"99","article-title":"Update on the treatment of chronic hepatitis C in HIV-infected patients","volume":"9","author":"Soriano","year":"2007","journal-title":"AIDS Rev"},{"key":"10.1157\/13126270_bib52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"Nu\u00f1ez","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13126270_bib53","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1157\/13126270_bib54","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1053\/j.gastro.2007.03.035","article-title":"Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy","volume":"132","author":"Lutchman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1157\/13126270_bib55","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.41.6.1231","article-title":"Effects of drugs on 2\u2019,3\u2019-dideoxy- 2\u2019,3\u2019-dydehydrothymidine phosphorylation in vitro","volume":"41","author":"Hoggard","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126270_bib56","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1128\/AAC.49.10.3997-4008.2005","article-title":"Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HIV-HCV coinfections: results of a randomized clinical study","volume":"49","author":"Rodr\u00edguez-Torres","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126270_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2893.2007.00846.x","article-title":"Risk factors for anemia in HIV\/HCV-coinfected patients treated with interferon plus ribavirin","volume":"14","author":"Bani-Sadr","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2893.2007.00952.x","article-title":"Incidence of anaemia and impact on sustained virological response in HIV\/HCV-coinfected patients treated with pegylated interferon plus ribavirin","volume":"15","author":"N\u00fa\u00f1ez","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib59","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/135965350701200805","article-title":"Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients","volume":"12","author":"Mira","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","article-title":"Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons","volume":"13","author":"\u00c1lvarez","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib61","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib63","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/498312","article-title":"Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment","volume":"41","author":"Bani-Sadr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126270_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1157\/13126270_bib65","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-base therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13126270_bib66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitocondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13126270_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep.20074","article-title":"Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine","volume":"2","author":"Walker","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib68","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"P\u00e9rez-Olmeda","year":"2003","journal-title":"AIDS"},{"issue":"Suppl","key":"10.1157\/13126270_bib69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy for hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13126270_bib70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/QAI.0b013e31802f12d3","article-title":"Incidence and risk factors for weight loss during dual HIV\/HCV therapy","volume":"44","author":"Re","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","article-title":"Weight loss in HIV-infected patients","volume":"347","author":"Garc\u00eda-Benayas","year":"2002","journal-title":"N Eng J Med"},{"key":"10.1157\/13126270_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2893.2007.00939.x","article-title":"Severe weight loss in HIV\/HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors","volume":"15","author":"Bani-Sadr","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1157\/13126270_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","article-title":"Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?","volume":"45","author":"Bani-Sadr","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126270_bib74","doi-asserted-by":"crossref","unstructured":"Vispo ME, Barreiro P, Pineda JA, Mira JA, Maida I, Mart\u00edn-Carbonero L, et al. Low response to pegylated plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. En prensa 2008.","DOI":"10.1177\/135965350801300303"},{"key":"10.1157\/13126270_bib75","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Efficacy of pegylated-interferon + ribavirin treatment in HIV\/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone","author":"Mira","year":"2008"},{"key":"10.1157\/13126270_bib76","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0091270006287704","article-title":"Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects","volume":"46","author":"Ramanathan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1157\/13126270_bib77","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkm373","article-title":"Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus\/ HIV-coinfected patients","volume":"60","author":"Pineda","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13126270_bib78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1310\/FRWE-HCGF-K3BG-DG8P","article-title":"Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin","volume":"6","author":"S\u00e1nchez-Conde","year":"2005","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13126270_bib79","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N England J Med"},{"key":"10.1157\/13126270_bib80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350601100413","article-title":"Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy","volume":"11","author":"Palacios","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1157\/13126270_bib81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc06-1075","article-title":"Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria","volume":"30","author":"Samaras","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1157\/13126270_bib82","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13126270_bib83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1310\/50JB-VNBB-7HRG-7GUR","article-title":"Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment","volume":"4","author":"Poizot-Martin","year":"2003","journal-title":"HIV Clin Trials"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T21:33:27Z","timestamp":1709415207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08765297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":83,"alternative-id":["S0213005X08765297"],"URL":"https:\/\/doi.org\/10.1157\/13126270","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}